These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25847652)

  • 1. Efficacy and safety concerns are important reasons why the FDA requires multiple reviews before approval of new drugs.
    Ross JS; Dzara K; Downing NS
    Health Aff (Millwood); 2015 Apr; 34(4):681-8. PubMed ID: 25847652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scientific and regulatory reasons for delay and denial of FDA approval of initial applications for new drugs, 2000-2012.
    Sacks LV; Shamsuddin HH; Yasinskaya YI; Bouri K; Lanthier ML; Sherman RE
    JAMA; 2014 Jan 22-29; 311(4):378-84. PubMed ID: 24449316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
    Moore TJ; Furberg CD
    JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010.
    Downing NS; Shah ND; Aminawung JA; Pease AM; Zeitoun JD; Krumholz HM; Ross JS
    JAMA; 2017 May; 317(18):1854-1863. PubMed ID: 28492899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IND application.
    Ferkany JW; Williams M
    Curr Protoc Pharmacol; 2008 Sep; Chapter 9():Unit 9.10. PubMed ID: 22294234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Food and Drug Administration approval process for ophthalmic drugs in the US.
    Lloyd R; Harris J; Wadhwa S; Chambers W
    Curr Opin Ophthalmol; 2008 May; 19(3):190-4. PubMed ID: 18408492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
    Shulman SR; Brown JS
    Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
    [No Abstract]   [Full Text] [Related]  

  • 10. Zohydro approval by food and drug administration: controversial or frightening?
    Manchikanti L; Atluri S; Candido KD; Boswell MV; Simopoulos TT; Grider JS; Falco FJ; Hirsch JA
    Pain Physician; 2014; 17(4):E437-50. PubMed ID: 25054396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. International Conference on Harmonisation; Guidance on S9 Nonclincal Evaluation for Anticancer Pharmaceuticals; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Mar; 75(44):10487-8. PubMed ID: 20383918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From idea to market: the drug approval process.
    Lipsky MS; Sharp LK
    J Am Board Fam Pract; 2001; 14(5):362-7. PubMed ID: 11572541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA designations for therapeutics and their impact on drug development and regulatory review outcomes.
    Kesselheim AS; Darrow JJ
    Clin Pharmacol Ther; 2015 Jan; 97(1):29-36. PubMed ID: 25670381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How Often Are Drugs Made Available Under the Food and Drug Administration's Expanded Access Process Approved?
    McKee AE; Markon AO; Chan-Tack KM; Lurie P
    J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S136-S142. PubMed ID: 28921646
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug approval and drug effectiveness.
    Spielmans GI; Kirsch I
    Annu Rev Clin Psychol; 2014; 10():741-66. PubMed ID: 24329178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Trial endpoints for drug approval in oncology: Chemoprevention.
    Beitz J
    Urology; 2001 Apr; 57(4 Suppl 1):213-5. PubMed ID: 11295630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Demographics of clinical trials participants in pivotal clinical trials for new molecular entity drugs and biologics approved by FDA From 2010 to 2012.
    Eshera N; Itana H; Zhang L; Soon G; Fadiran EO
    Am J Ther; 2015; 22(6):435-55. PubMed ID: 25621972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tutorial on How the US Food and Drug Administration Regulates Parenteral Nutrition Products.
    Tabor E
    JPEN J Parenter Enteral Nutr; 2020 Feb; 44(2):174-181. PubMed ID: 31971272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Examination of risk evaluation and mitigation strategies and drug safety in the US.
    Rodriguez-Monguio R; Spielberger K; Seoane-Vazquez E
    Res Social Adm Pharm; 2014; 10(1):232-8. PubMed ID: 23611865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.